


#4A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re patent application of  
David MU *et al.*

Attorney Docket No: 38002-0024

Confirmation No.: 2406

Application No.: 10/073,060

Group Art Unit: 1645

Filed: February 12, 2002

Examiner: Unassigned

For: AMPLIFIED CANCER GENE HEPSIN

AMENDMENT IN RESPONSE TO NOTICE  
UNDER 37 CFR §§ 1.821 – 1.825

Commissioner for Patents  
Washington, D.C. 20231  
**Box SEQUENCE**

Sir:

In response to the Notice to File Missing Parts in connection with Requirements for Applications containing Sequence Disclosures mailed April 16, 2002, please amend the application as follows:

IN THE SPECIFICATION:

Page 36, line 10, paragraph 2: Please amend as follows:

a1

**Hepsin: A trypsin-like serine protease:** The GenBank entry M18930 *Homo sapiens*, hepsin gene is as shown below (SEQ ID NO: 1):

Page 37, line 1, paragraph 1: Please amend as follows:

a2

**Hepsin Protein sequence (SEQ ID NO: 2):**

Page 65, line 18, paragraph 6: Please amend as follows:

a3

Reverse transcriptase (RT)-directed quantitative PCR was performed using the TaqMan 7700 Sequence Detector (Applied Biosystems) to determine the hepsin mRNA level in each sample. Human beta-actin mRNA was used as control. The nucleotide sequences of the hepsin TaqMan probe set used for the detection of mRNA levels detection were: